Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Lenalidomide

Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles (6 cycles = 1 course of Revlimid consolidation). Revlimid will be initiated at 5mg and can be dose escalated at the start of each cycle based on individual patient tolerability to a maximum of 25 mg. The total number of treatment cycles cannot exceed 12 cycles or two courses of six cycles each.

Trial Locations (1)

92093-0698

Moores UCSD Cancer Center, La Jolla

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Thomas Kipps

OTHER